Last updated: May 25, 2026
Executive summary: Prucalopride succinate supply chains typically split into (1) active pharmaceutical ingredient (API) manufacture by chemistry-focused producers and (2) finished-dose manufacturing by branded/generic API-to-tablet formulators and fill-finish contract manufacturing organizations (CMOs). For business planning, the critical procurement filters are FDA/EMA regulatory status of manufacturing sites, DMF/CEP coverage for prucalopride substance and excipients, and whether the supplier can support a Paragraph IV/ANDA strategy or only compliant non-challenge commercial supply. Without jurisdiction-specific listing and facility-level regulatory datasets, a complete, compliant roster of named “suppliers” cannot be produced.
Which companies supply prucalopride succinate API?
Short answer: Prucalopride succinate API supply is concentrated among API manufacturers that can hold or support drug master file (DMF) submissions and supply prucalopride intermediate chains under validated impurity and polymorph controls.
API sourcing structure
Prucalopride succinate procurement usually involves:
- API manufacturers producing prucalopride free base then forming the succinate salt under controlled crystallization conditions.
- Intermediate supply from upstream chemical vendors (not always visible in finished-dose supply disclosures).
- DMF-backed substance supply for generic development, enabling ANDA referencing or cross-referencing (subject to jurisdiction).
What supplier eligibility depends on
A credible API supplier for prucalopride succinate typically must support:
- DMF or CEP pathway coverage (for EU) for the drug substance.
- Traceability for genotoxic impurity control (method, acceptance criteria, batch records).
- Salt formation reproducibility for consistent dissolution and impurity profile.
Who manufactures prucalopride succinate tablets (finished dosage form)?
Short answer: Finished-dose tablet manufacturing is usually handled by manufacturers with validated solid oral dose capacity and regulatory documentation for prucalopride succinate tablets, including compression, coating, and packaging.
Tablet manufacturing segments
- Blending and compression lines suitable for dose units with controlled content uniformity.
- Film-coating and packaging lines meeting stability and leachables/extractables controls.
- Batch-size flexibility to support launch quantities and lifecycle supply.
What matters for procurement
- Regulatory status of the specific facility used (inspection history).
- Ability to meet dissolution specs and impurity limits aligned with the reference product.
- Supply continuity for generic launches where lead times tighten.
Are there contract manufacturers for prucalopride succinate (CMO/CDMO)?
Short answer: CDMO/CMO involvement is common for solid oral dose development and commercialization, but named supplier attribution requires facility-level regulatory listing or public DMF/plant disclosures tied to the drug.
CDMO scope commonly offered
- Analytical method transfer (assay, impurities, dissolution, polymorph monitoring).
- Scale-up of salt formation and crystallization.
- Tech transfer for tablet manufacturing and packaging.
Which prucalopride succinate suppliers support ANDA filings or generic launches?
Short answer: Suppliers that support ANDA readiness are those able to provide DMF-backed drug substance and development-grade documentation for quality-system and CMC alignment.
ANDA-relevant supplier deliverables
- DMF cross-reference or listed DMF support for prucalopride substance.
- Batch release testing documentation packages suitable for ANDA Module 3.
- Stability study plans aligned to intended shelf life and packaging configuration.
What is the regulatory status of prucalopride succinate that affects supplier choice?
Short answer: Supplier selection for prucalopride succinate must align with the jurisdiction’s approved manufacturing sites, quality system compliance, and whether the product is marketed as a branded reference, authorized generic, or via Abbreviated New Drug Application.
FDA/EMA practical constraints
- FDA: ANDA approval depends on drug substance controls and facility compliance for the product and drug substance as represented in the submission.
- EMA: marketing authorization depends on manufacturing site GMP status and, where applicable, CEP/DMF equivalence.
What documentation should you require from prucalopride succinate suppliers?
Short answer: Procurement teams typically require documentation that ties the supplier’s process and quality system to consistent impurity control and dosage-form performance.
Minimum CMC/quality package to request
- DMF or CEP number(s) for the drug substance, where applicable by jurisdiction.
- Specifications for assay, impurities, residual solvents, and water content.
- Polymorph/salt form control strategy for prucalopride succinate.
- Certificate of Analysis (CoA) for multiple recent lots (API and finished tablets, if bundled).
- Stability protocol and ongoing stability summaries.
How do logistics and supply continuity risks show up in prucalopride succinate procurement?
Short answer: Risks cluster around API crystallization/salt-form manufacturing capacity, single-site bottlenecks, and inspection outcomes for tableting/packaging lines.
Key continuity filters
- Dual-sourcing feasibility for API and key intermediates.
- Defined lead times for API release testing and tablet packaging.
- Prior manufacturing site inspections and remediation history.
How does prucalopride succinate supplier strategy differ for branded vs generic procurement?
Short answer: Branded procurement prioritizes long-term supply guarantees, while generic procurement prioritizes dossier readiness and CMC defensibility against regulatory scrutiny.
Branded supply posture
- Longer-term framework contracts.
- Tight change control (process, raw materials, packaging).
Generic launch posture
- Fast tech transfer with CMC-ready batch records.
- Tight alignment of dissolution and impurity profile to the approved reference.
What sourcing model best supports prucalopride succinate scale-up?
Short answer: Most scale-up programs favor a controlled handoff from development to commercial-grade API crystallization and then to finished-dose compression/coating under a single change-control umbrella.
Operational approach
- Select API supplier for salt formation robustness and impurity control.
- Select finished-dose CMO for consistent dissolution and content uniformity.
- Lock analytical methods early to reduce transfer friction.
Key Takeaways
- Prucalopride succinate supply typically splits into API producers plus tablet finished-dose manufacturers or CDMOs.
- Supplier qualification is dominated by jurisdiction-specific regulatory status, DMF/CEP coverage, impurity and salt-form control, and inspection-readiness of manufacturing sites.
- Generic-focused procurement depends on dossier-ready CMC documentation more than on list-price sourcing.
FAQs
- What DMF/CEP coverage is required to source prucalopride succinate API for ANDAs?
- What quality tests matter most for prucalopride succinate salt form consistency in API lots?
- How do dissolution specification and impurity profile differences affect prucalopride succinate generic manufacturing tolerances?
- Which manufacturing steps are the main bottlenecks in solid oral dosage supply of prucalopride succinate tablets?
- What documentation should a finished-dose CMO provide to support regulatory submission for prucalopride succinate?
References (APA)
- FDA. (n.d.). ANDA submission information and guidance. U.S. Food and Drug Administration.
- EMA. (n.d.). GMP, CEP and quality guidance for medicinal products. European Medicines Agency.
- ICH. (n.d.). ICH Q3A/Q3B/Q3C and related guidance on impurities and residual solvents. International Council for Harmonisation.
